52w high/low | ₹1034.8 / ₹401 |
P/E ratio | 51.28 |
Dividend | 0.26 |
ROE | 20.41 |
ROCE | 26.25 |
Face value | 2 |
Book value | ₹182.89Cr |
Market capital | ₹14,356.33Cr |
What is shareholding pattern? Who are shareholders?
What is a cash flow statement?
What is a balance sheet?
What is a profit and loss statement?
What are dividends?
What are bonuses?
Incorporated in the year 16th April, 1990 Caplin Point Laboratories was promoted by P C Partheeban, T Palanisamy, S Karunakaran, S Jayaraman and B A Ahmed. The company manufactures pharmaceutical formulations in the form of tablets, ointments and capsules, liquid orals and oral powders. As on 31 March 2019, the Company has four subsidiaries, viz Caplin Steriles Limited, Argus Salud Pharma LLP, Caplin Point Far East Limited - Hongkong and Caplin Point Laboratories Colombia SAS- Colombia. The company came out with a public issue in Nov. '94 and expanded its production capacity by setting up a new unit to manufacture its range of products, at Pondicherry. The company has retained its SSI status even after the expansion and thus will be out of the purview of the DPCO. During 1993-94, Triwin (a partnership firm) was merged with Caplin Point. The company entered into a technical agreement with American Remedies and Concord Laboratories, US, for specific products, with a 30% buyback arrangement.